Multimodal magnetic resonance and near-infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode-dual-gadolinium liposomal contrast agent
Vikas Kundra, M.D., Ph.D. is Professor and Director of Molecular Imaging in the Department of Radiology, U.T.-M.D. Anderson Cancer Center with joint appointment in the Department of Cancer Systems Imaging. He received his M.D. and Ph.D. from Harvard University and completed his radiology training at Brigham and Women’s Hospital. He is a Fellow of the Society of Body Computed Tomography-Magnetic Resonance Imaging and a Distinguished Investigator of the Academy of Radiology Research. Clinical work focuses on Body Imaging particularly in cancer and research focuses on molecular imaging, including imaging of gene expression and nanotechnology.
The degree of cytoreduction at surgery is a major prognostic factor for ovarian cancer.A multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual Gd-ICG) contrast agent can be used to visualize intraperitoneal ovarian tumors by multimodal MR and near infra-red imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, p<0.05, n=6). As seen on laparotomy and excised tumors views and confirmed by radiant efficiency measurement, Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p<0.05, n=6). This suggests clinical potential to localize ovarian tumors by MR for staging and surgical planning, and, by NIR at surgery for resection.